Literature DB >> 11672475

Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro.

S Maayani1, T Schwarz, B Craddock-Royal, T M Tagliente.   

Abstract

Platelet aggregation requires the concomitant activation of at least one G(i)- and one G(q)-coupled receptor. Epinephrine (EPI) amplifies the response elicited by a number of agonists for platelet aggregation. This study tested the hypothesis that platelet alpha(2A)-adrenoceptor activation causes deceleration of the deaggregation component of the platelet aggregation response when activated concomitantly with the G(q)-coupled adenosine diphosphate (ADP) P2Y(1) or 5-hydroxytryptamine(2A) receptor. The time course of the aggregation response of human platelet-rich plasma following activation of combinations of two or three receptors was assessed by turbidometry using lepirudin anticoagulation. Simultaneous activation of specific two- and three-receptor combinations was achieved using selective antagonists for the P2Y(12) and P2Y(1) receptor subtypes. Steady-state and kinetic parameters, obtained using a four-compartment kinetic model, were used to assess the effects on the net aggregation response. Graded alpha(2A)-adrenoceptor activation was associated with a concentration-dependent decrease of the rate constant of deaggregation. Activation of both ADP receptor subtypes and the alpha(2A)-adrenoceptor produced a concentration-dependent, mutual amplification of the aggregation response. In addition, when three receptors were simultaneously activated, mutual amplification of the aggregation response was observed at physiologically relevant concentrations of epinephrine or norepinephrine (NE) and ADP. We propose that similar to the P2Y(12) receptor, activation of the alpha(2A)-adrenoceptor decelerates the deaggregation component shifting the balance toward increased net aggregation. The effects of EPI and NE on the aggregation response may contribute to the mechanism of increased thrombotic risk present in certain pathophysiological and disease states.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672475     DOI: 10.1080/09537100120078403

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  4 in total

1.  Modified mandated choice for organ procurement.

Authors:  P Chouhan; H Draper
Journal:  J Med Ethics       Date:  2003-06       Impact factor: 2.903

2.  Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.

Authors:  Fadila Guessous; Marek Marcinkiewicz; Renata Polanowska-Grabowska; Sudawadee Kongkhum; Daniel Heatherly; Tom Obrig; Adrian R L Gear
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 3.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Reduced platelet serotonergic responsivity as assessed by dense granule secretion in first-episode psychosis.

Authors:  Ravinder D Reddy; Matcheri S Keshavan; Jeffrey K Yao
Journal:  Clin Biochem       Date:  2007-05-24       Impact factor: 3.281

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.